Skip to Main Content

Author Details

Claudia Maria Hattinger
IRCCS Istituto Ortopedico Rizzoli
1996
75
32
PMIDPaper TitleJournal TitlePublished Year
36614241Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma.Int J Mol Sci2023
37596165Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma.Cancer Epidemiol2023
38074116Single-nucleotide polymorphism profiling by multimodal-targeted next-generation sequencing in methotrexate-resistant and -sensitive human osteosarcoma cell lines.Front Pharmacol2023
36614241Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma.Int J Mol Sci2023
37596165Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma.Cancer Epidemiol2023
38074116Single-nucleotide polymorphism profiling by multimodal-targeted next-generation sequencing in methotrexate-resistant and -sensitive human osteosarcoma cell lines.Front Pharmacol2023
36233089Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing.Int J Mol Sci2022
36233089Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing.Int J Mol Sci2022
34207685Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies.Cancers (Basel)2021
34207685Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies.Cancers (Basel)2021
34572110Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?Cells2021
34572110Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?Cells2021
32155954ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma.Cells2020
32191290Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.JAMA Oncol2020
32351889Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group.Front Oncol2020
32295254Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors.Cells2020
32155954ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma.Cells2020
32211337Cisplatin Resistance in Osteosarcoma: <i>In vitro</i> Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments.Front Oncol2020
32656080Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group.Front Oncol2020
32599901Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.Int J Mol Sci2020
32629971Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.Int J Mol Sci2020
32656080Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group.Front Oncol2020
32629971Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.Int J Mol Sci2020
32599901Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.Int J Mol Sci2020
32211337Cisplatin Resistance in Osteosarcoma: <i>In vitro</i> Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments.Front Oncol2020
32351889Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group.Front Oncol2020
32295254Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors.Cells2020
32191290Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.JAMA Oncol2020
30430199Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma.Cell Mol Life Sci2019
30430199Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma.Cell Mol Life Sci2019
30822170Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.Expert Opin Drug Metab Toxicol2019
31401903An update on emerging drugs in osteosarcoma: towards tailored therapies?Expert Opin Emerg Drugs2019
31047947Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.Cancer Lett2019
31401903An update on emerging drugs in osteosarcoma: towards tailored therapies?Expert Opin Emerg Drugs2019
30822170Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.Expert Opin Drug Metab Toxicol2019
31047947Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.Cancer Lett2019
29210060Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.Int J Cancer2018
30324828Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?Expert Rev Mol Diagn2018
29210060Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.Int J Cancer2018
30324828Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?Expert Rev Mol Diagn2018
27241064The pharmacogenomics of osteosarcoma.Pharmacogenomics J2017
27241064The pharmacogenomics of osteosarcoma.Pharmacogenomics J2017
27852114Polymorphisms of genes related to metotrexate response and toxicity in high-grade osteosarcoma.Expert Opin Drug Metab Toxicol2017
27758143Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.Expert Opin Drug Metab Toxicol2017
28183198Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?Future Oncol2017
28183198Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?Future Oncol2017
27852114Polymorphisms of genes related to metotrexate response and toxicity in high-grade osteosarcoma.Expert Opin Drug Metab Toxicol2017
27758143Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.Expert Opin Drug Metab Toxicol2017
27466354Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.Mol Cancer Ther2016
27120394H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance.J Med Chem2016
  • 1 - 50 of 150

Recommended Authors

Ana Teresa Amaral
Instituto de Salud Carlos III
Career Start Year 2009
Number of shared co-authors 8
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 2
Wendong Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 2
Thomas G P Gr??newald
German Cancer Research Center
Career Start Year 2006
Number of shared co-authors 24
Joseph A Ludwig
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 6
Ji Zhang
Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine
Career Start Year 2004
Number of shared co-authors 0
Sandra J Strauss
University College London, Cancer Institute
Career Start Year 2003
Number of shared co-authors 14
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 1
Michelle J Henderson
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year 2002
Number of shared co-authors 7
Ga??lle Pierron
Institut Curie Hospital
Career Start Year 2001
Number of shared co-authors 21
Jilong Yang
Tianjin Medical University Cancer Institute and Hospital
Career Start Year 2000
Number of shared co-authors 0
Piergiorgio Modena
S. Anna General Hospital
Career Start Year 2000
Number of shared co-authors 1
Oscar M Tirado
Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)/CIBERONC
Career Start Year 2000
Number of shared co-authors 8
Franck Tirode
Cancer Center of Lyon
Career Start Year 1997
Number of shared co-authors 21
Karoly Szuhai
Leiden University Medical Center
Career Start Year 1997
Number of shared co-authors 11
Jaume Mora
Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu
Career Start Year 1996
Number of shared co-authors 7
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 3
Uta Dirksen
University Hospital Essen, West German Cancer Center
Career Start Year 1994
Number of shared co-authors 28
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 2
Javed Khan
Center for Cancer Research, National Cancer Institute
Career Start Year 1993
Number of shared co-authors 35
Enrique de Alava
Servicio de Anatomia Patologica. Hospital Universitario Virgen del Rocio.
Career Start Year 1992
Number of shared co-authors 20
Eberhard Korsching
Institutet of Bioinformatics, University Hospital of Munster, University of Munster
Career Start Year 1990
Number of shared co-authors 6
Poul H Sorensen
British Columbia Cancer Research Centre
Career Start Year 1989
Number of shared co-authors 19
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 5
Suzanne Kamel-Reid
Toronto General Hospital, University Health Network, University of Toronto
Career Start Year 1988
Number of shared co-authors 4
Susan A Burchill
Leeds Institute of Medical Research, St. James's University Hospital
Career Start Year 1986
Number of shared co-authors 7
David M Loeb
Children's Hospital at Montefiore.
Career Start Year 1986
Number of shared co-authors 5
Jeffrey A Toretsky
Georgetown University Medical Center, Georgetown University
Career Start Year 1986
Number of shared co-authors 16
Marc Ladanyi
Memorial Sloan Kettering Cancer Center
Career Start Year 1984
Number of shared co-authors 26
Ola Myklebost
Institute for Cancer Research, Oslo University Hospital
Career Start Year 1983
Number of shared co-authors 16

Collaborators

Massimo Serra
IRCCS Istituto Ortopedico Rizzoli
Co-authored papers 54
Piero Picci
IRCCS Istituto Ortopedico Rizzoli
Co-authored papers 35
Katia Scotlandi
IRCCS Istituto Ortopedico Rizzoli
Co-authored papers 25
Peter F Ambros
Children's Cancer Research Institute, Medical University of Vienna
Co-authored papers 12
Chiara Riganti
University of Turin
Co-authored papers 10
Lisa Mirabello
National Cancer Institute
Co-authored papers 7
Richard Gorlick
University of Texas MD Anderson Cancer Center
Co-authored papers 7
Ana Pati??o-Garc??a
Center for Applied Medical Research.
Co-authored papers 7
Sharon A Savage
Clinical Genetics Branch, National Cancer Institute (NCI)
Co-authored papers 7
Fernando Lecanda
University of Navarra, Center for Applied Medical Research
Co-authored papers 7
Adrienne M Flanagan
University College London, UCL Cancer Institute
Co-authored papers 7
Stephen J Chanock
National Cancer Institute, National Institutes of Health
Co-authored papers 7
Logan G Spector
Division of Epidemiology and Clinical Research, University of Minnesota
Co-authored papers 6
Jay S Wunder
University of Toronto
Co-authored papers 6
Irene L Andrulis
University of Toronto
Co-authored papers 6
David M Thomas
Garvan Institute of Medical Research
Co-authored papers 6
Meredith Yeager
Frederick National Laboratory for Cancer Research
Co-authored papers 6
Donald A Barkauskas
Keck School of Medicine of the University of Southern California
Co-authored papers 6
Inge M Ambros
St. Anna Children's Cancer Research Institute
Co-authored papers 6
Julie M Gastier-Foster
Baylor College of Medicine
Co-authored papers 6
Margaret A Tucker
National Cancer Institute
Co-authored papers 6
Roberto Tirabosco
University College London, UCL Cancer Institute
Co-authored papers 6
Robert N Hoover
National Cancer Institute
Co-authored papers 5
Nalan Gokgoz
Lunenfeld-Tanenbaum Research Institute
Co-authored papers 5
Sakari Knuutila
Co-authored papers 5
Fernanda Amary
Royal National Orthopaedic Hospital
Co-authored papers 5
Luis Sierrases??maga
Clinica Universidad de Navarra
Co-authored papers 4
Neyssa Marina
Stanford University School of Medicine
Co-authored papers 4
Joseph F Fraumeni
National Cancer Institute
Co-authored papers 4
Silvia Regina Caminada de Toledo
Pediatric Oncology Institute (IOP/GRAACC), Federal University of Sao Paulo
Co-authored papers 4
Release 1.2